Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
Shares of US clinical-stage drugmaker Moleculin Biotech were going through the roof, leaping 1,228% to $6.11 in early trading, as the company updated on its lead candidate’ 25 March 2024
Biotechnology
Ultomiris (ravulizumab-cwvz) has been approved in the USA as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). 25 March 2024
Biotechnology
Invivyd closed 41% higher after Friday’s trading in New York. 25 March 2024
Pharmaceutical
Swedish biotech Sobi has announced positive results from the AVA-PED-301 study, evaluating the efficacy and safety of Doptelet (avatrombopag). 25 March 2024
Biotechnology
Danish diabetes and obesity giant Novo Nordisk is continuing its deal-making and M&A activity, today revealing plans to add to its cardiovascular portfolio. 25 March 2024
Biotechnology
On the M&A front last week, UK pharma major AstraZeneca announced an agreement to acquire Canadian radiopharma company Fusion Pharmaceuticals for $2 billion upfront and a further $400 million contingent. Crinetics Pharmaceuticals released new Phase III data on its investigational drug paltusotine in acromegaly. Japanese drugmaker Kyowa Kirin’s subsidiary Orchard Therapeutics set out US launch plans for its newly Food and Drug Administration (FDA) approved rare disease cell therapy Lenmeldy with a list price of $4.25 million. Also of note, on the regulatory front, Japan’s largest drugmaker Takeda gained an expanded indication for its Iclusig for leukemia. 25 March 2024
Biotechnology
An Expert View from Tomislav Kamenski, Senior Director, Therapy Area Market Access Leader, Hematology, Johnson & Johnson. 25 March 2024
Biotechnology
The Phase III KEYLYNK-006 trial evaluating Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, in combination with maintenance Lynparza (olaparib), a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic non-squamous non-small cell lung cancer (NSCLC). 22 March 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its March 2024 meeting. 22 March 2024
Pharmaceutical
Validating Novo Nordisk’s decision to research the cardiovascular impact of Wegovy (semaglutide), US authorities have said Medicare patients with heart problems can now receive the drug. 22 March 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze